Immunotherapy after surgery and chemoradiation for cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests adding the immunotherapy drug Zimberelimab to standard chemoradiation after surgery for locally advanced cervical cancer. It aims to see if this combination helps prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of cervical cancer called squamous cell, adenocarcinoma, or adenosquamous carcinoma.
- You must have had radical surgery to remove the cancer.
- You must be between 18 and 70 years old.
- You must be in good enough health to be up and moving around (ECOG score 0 or 1).
- You cannot have received immunotherapy before.
- You cannot have an active autoimmune disease or infection that needs treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a tailored “extra” treatment after surgery—guided by a lab test called minimal residual disease (MRD)—can reduce the risk of cervical cancer coming back. It focuses on people with certain stages of cervical cancer who can follow the treatment plan and study follow-up.
This study tests whether combining immunotherapy with chemotherapy, followed by radiation plus immunotherapy, can work better than standard treatment for cervical cancer. It aims to help patients whose cancer has not spread yet.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy before surgery for cervical cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a combination of three types of cancer-fighting drugs—an immunotherapy (camrelizumab), a targeted therapy (famitinib), and chemotherapy—to treat cervical cancer that has returned or spread. The goal is to see if this combination works better than standard treatment.
This trial tests if giving chemotherapy plus an immunotherapy drug before surgery can help shrink tumors and improve outcomes for patients with stage IB2 cervical cancer that has not been treated yet. It might be an option if you have a specific type of cervical cancer that shows a certain protein (PD-L1) on your tumor cells.
This trial tests whether adding tislelizumab to standard chemotherapy and radiation works better as first treatment for stage IIIC2 cervical cancer. It aims to improve how well the cancer responds and controls the disease.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.